Cordlife proposes to merge with NY-listed life sciences enterprise
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
CORDLIFE Group on Tuesday said that it has made an indicative, non-binding and conditional proposal to merge with New York-listed Global Cord Blood Corporation.
Global Cord Blood Corporation provides cord blood collection, laboratory testing, haematopoietic stem cell processing and stem cell storage services in China. It is incorporated in the Cayman Islands and listed on the New York Stock Exchange (NYSE).
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Singaporeans can now buy record amount of yen per Singdollar
